Hat Vla Fr0004056851 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hat vla fr0004056851. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hat Vla Fr0004056851 Today - Breaking & Trending Today

Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members

Saint-Herblain , June 24, 2022 – Valneva SE , a specialty vaccine company, today announced that all the resolutions recommended by the Management Board were approved by the shareholders at its. | June 24, 2022 ....

United States , France General , Anne Marie Graffin , Joshua Drumm , James Sulat , James Edward Connolly , Vp Global Communications European Investor Relations , Drug Administration , Euronext Paris , Management Board , Annual General Meeting , Supervisory Board , Supervisor Board , Large Venture Investments , Bpifrance Large Venture , Investment Director , Fonds Strat , Edward Connolly , Executive Vice President , General Manager , Wyeth Vaccines , Biologics License Application , Valneva Se Stock Exchange , Press Release , Hat Vla Fr0004056851 ,

Valneva : to Participate in Goldman Sachs Eleventh Annual Biotech Symposium (Form 6-K)

Valneva to Participate in Goldman Sachs Eleventh Annual Biotech Symposium

Saint-Herblain , September 1, 2021 - Valneva SE , a specialty vaccine company, today announced that its. | September 4, 2021 ....

David Lawrence , Goldman Sachs , Joshua Drumm , Thomas Lingelbach , Investor Relations Corporate Communications , Goldman Sachs Eleventh Annual Biotech , Euronext Paris , Goldman Sachs Eleventh Annual Biotech Symposium , Chief Executive Officer Thomas Lingelbach , Chief Financial Officer David Lawrence , Investor Relations , Global Investor , Valneva Se Stock Exchange , Press Release , Hat Vla Fr0004056851 ,

Valneva : and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate

Pfizer Forward-Looking Statements
The information contained in this release is as of March 8, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about a Lyme disease vaccine candidate, VLA15, and a collaboration between Pfizer and Valneva for VLA15, including their potential benefits and a potential phase 3 start, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorabl ....

United States , New York , Kathrin Jansen , Bryan Dunn , Juan Carlos Jaramillo , Jerica Pitts , Us Centers For Disease , Drug Administration , Exchange Commission , Pfizer Inc , Head Of Pfizer Vaccine Research , Investor Relations Corporate Communications , Senior Vice President , Pfizer Vaccine Research , Carlos Jaramillo , Chief Medical Officer , North America , Fast Track , Primary Endpoint , Booster Phase , Disease Control , Breakthroughs That Change Patient , Annual Report , Looking Information , Factors That May Affect Future , Lyme Report ,